Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

The swelling started with almost no warning, then seven-year-old Fiona Wardman’s hand ballooned like a rubber glove hooked to ...

The allergy and immunology community mourns the loss of Marcus Maurer, MD, executive director of the Institute of Allergology ...

Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study ...

Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Astria Therapeutics (ATXS – Research Report). The associated ...

Intellia Therapeutics shifts focus to NTLA-2002 for hereditary angioedema and nex-z for ATTR amyloidosis, advancing Phase 3 trials in 2025. Strategic reorganization includes a 27% workforce ...

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026 Enrollment in RAPIDe-3 ...

“We had no idea what it was,” says Wardman. She was terrified. The swollen hand of a patient with hereditary angioedema.Credit: HAE Australasia / Supplied As she hit puberty, the attacks ...